MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 05-16-2026
PLx Pharma Cash and Cash Equivalents 2011-2026 | PLXP
Annual Cash and Cash Equivalents PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 69.4 M | 22.4 M | 14 M | 14.3 M | 24.4 M | 59.3 K | 91.7 K | 27 M | 3.86 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.4 M | 59.3 K | 19.5 M |
Quarterly Cash and Cash Equivalents PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 25.8 M | 35.7 M | 52.5 M | 69.4 M | 82.6 M | 80.2 M | 84.4 M | 22.4 M | 9.09 M | 13.3 M | 9.29 M | 14 M | 18.5 M | 21.3 M | 24.3 M | 14.3 M | 16.5 M | 17.9 M | 20.4 M | 24.4 M | 30.4 M | 25.1 M | 12.4 M | 59.3 K | 7.84 M | 7.59 M | 4.17 M | 91.7 K | 9.19 M | 28.7 M | 24 M | 27 M | 29.9 M | 32.6 M | 36.1 M | 3.86 M | 3.86 M | 3.86 M | 3.86 M | 1.46 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 84.4 M | 59.3 K | 23.7 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
13.6 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.4 M | $ 5.5 | -3.85 % | $ 81.7 M | USA |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
974 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
11 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
792 M | $ 2.76 | -1.08 % | $ 1.06 B | Canada |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
72.9 M | $ 37.06 | 10.76 % | $ 1.36 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
93.7 M | $ 2.52 | 1.41 % | $ 319 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 1.02 | - | $ 110 M | Canada |
 |
Pacira BioSciences
PCRX
|
277 M | $ 23.44 | 0.99 % | $ 1.08 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 1.09 | -1.8 % | $ 1.35 M | USA |
 |
Solid Biosciences
SLDB
|
59.9 M | $ 6.46 | -1.67 % | $ 565 M | USA |
 |
Aurora Cannabis
ACB
|
138 M | $ 3.3 | -2.43 % | $ 181 M | Canada |
 |
Jupiter Wellness
JUPW
|
2.28 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
107 M | $ 1.08 | -0.46 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
207 M | $ 5.11 | -1.26 % | $ 3.16 B | Canada |
 |
Evolus
EOLS
|
53.8 M | $ 6.73 | 0.45 % | $ 434 M | USA |
 |
Sundial Growers
SNDL
|
252 M | $ 1.46 | -0.34 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
205 M | $ 8.17 | 2.96 % | $ 437 M | USA |
 |
Veru
VERU
|
15.8 M | $ 3.05 | -1.77 % | $ 44.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
104 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
2.26 M | $ 0.7 | -1.61 % | $ 2.82 M | USA |
 |
Assertio Holdings
ASRT
|
10.2 M | $ 23.49 | 0.11 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
90 K | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
1.31 B | $ 5.23 | 1.06 % | $ 1.94 B | Canada |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
3.5 M | $ 6.45 | 2.79 % | $ 255 M | USA |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
84.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
21.3 M | $ 4.32 | -0.92 % | $ 216 M | USA |
 |
Viatris
VTRS
|
1.32 B | $ 15.87 | -2.04 % | $ 18.5 B | USA |
 |
Zomedica Corp.
ZOM
|
9.02 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
10.7 M | $ 0.67 | -2.13 % | $ 24.1 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
345 K | $ 0.75 | 3.79 % | $ 3.22 M |  China |
 |
TherapeuticsMD
TXMD
|
7.48 M | $ 1.88 | -0.27 % | $ 21.7 M | USA |